Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Prostatic Neoplasms 12Lymphoma, Non-Hodgkin 8Wilms Tumor 7Sarcoma 7Glioma 7Rhabdoid Tumor 6Neuroectodermal Tumors, Primitive, Peripheral 6Neuroblastoma 6Multiple Myeloma 6Medulloblastoma 6Lymphoma 6Histiocytosis, Langerhans-Cell 6Hepatoblastoma 6Ependymoma 6Rhabdomyosarcoma 5Osteosarcoma 5Central Nervous System Neoplasms 5Pancreatic Neoplasms 4Mouth Neoplasms 4Leukemia, Myeloid, Acute 4Colorectal Neoplasms 4Breast Neoplasms 4Sarcoma, Ewing 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic Syndromes 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Thyroid Cancer, Papillary 2

Interventions

canakinumab 1X-Rays 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Clonal Cytopenia of Undetermined Significance × X-Rays × Clear all
NCT05641831 2026-01-02

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
110 enrolled
Classical hematology

Clonal Cytopenia of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡